Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 4,247 | 463 | 3,726 |
| Samples | 818 | 139 | 665 |
| Peptides | 627 | 103 | 546 |
Function
NRG3 · Neuregulin 3
This gene is a member of the neuregulin gene family. This gene family encodes ligands for the transmembrane tyrosine kinase receptors ERBB3 and ERBB4 - members of the epidermal growth factor receptor family. Ligand binding activates intracellular signaling cascades and the induction of cellular responses including proliferation, migration, differentiation, and survival or apoptosis. This gene encodes neuregulin 3 (NRG3). NRG3 has been shown to activate the tyrosine phosphorylation of its cognate receptor, ERBB4, and is thought to influence neuroblast proliferation, migration and differentiation by signalling through ERBB4. NRG3 also promotes mammary differentiation during embryogenesis. Linkage studies have implicated this gene as a susceptibility locus for schizophrenia and schizoaffective disorder. Alternative splicing results in multiple transcript variants encoding distinct isoforms. Additional transcript variants have been described but their biological validity has not been verified.[provided by RefSeq, Sep 2009].
Isoforms & Proteins
7 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 517 amino-acid changes on canonical ENST00000372141 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in NRG3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NRG3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Endometrial Carcinoma | 12/42 29% | 28/612 5% |
| Melanoma | 12/210 6% | 101/1899 5% |
| Non-Small Cell Lung Carcinoma | 30/304 10% | 58/1390 4% |
| Squamous Cell Lung Carcinoma | 7/57 12% | 36/810 4% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| Gastric Carcinoma | 2/74 3% | 73/1809 4% |
| Colorectal Carcinoma | 22/143 15% | 87/3239 3% |
| Esophageal Carcinoma | 0/23 0% | 23/769 3% |
| Other Solid Cancers | 1/94 1% | 36/1515 2% |
| Small Cell Lung Carcinoma | 0/9 0% | 15/752 2% |
| Hepatocellular Carcinoma | 1/46 2% | 37/2210 2% |
| Neuroendocrine Tumour | 2/154 1% | 10/577 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Head and Neck Carcinoma | 0/85 0% | 23/1574 1% |
| Mesothelioma | 3/62 5% | 0/165 0% |
| Bladder Carcinoma | 0/58 0% | 13/956 1% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 30/2550 1% |
| Cervical Carcinoma | 1/35 3% | 4/422 1% |
| Other Sarcomas | 3/69 4% | 5/699 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Ewings Sarcoma | 3/63 5% | 0/262 0% |
| Biliary Tract Carcinoma | 0/54 0% | 8/950 1% |
| Non-Cancerous | 0/104 0% | 7/830 1% |
| Ovarian Carcinoma | 5/109 5% | 3/998 0% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| B-Cell Non-Hodgkins Lymphoma | 4/88 5% | 13/2534 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 9/1592 1% |
| Prostate Carcinoma | 1/13 8% | 11/2105 1% |
Mutation Distribution
Where NRG3 is mutated · all tissues, split by cell line vs tissue
How many mutations in NRG3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 50 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 4,247 mutations in NRG3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|